LifeSci Capital initiated coverage of Oruka Therapeutics with an Outperform rating and $41 price target. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’ Hot Stocks on TipRanks >> Read More on ORKA: Oruka Therapeutics initiated with a Buy at TD Cowen Oruka Therapeutics Secures $200M to Advance Skin Disease Treatments Oruka initiated with a Buy at Jefferies Oruka announces $200M private placement Oruka Therapeutics Announces $200 Million Private Placement Disclaimer & DisclosureReport an Issue
